Ophthalmics Partnering Terms and Agreements -





Published: February 2014 | Pages: 781 | Format: PDF

The Ophthalmics Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter ophthalmics partnering deals. The majority of deals are discovery, preclinical or development stage whereby the licensee obtains a right or an option right to license the licensors ophthalmics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

This report provides details of the latest ophthalmics deals and contracts announced in the healthcare sectors. 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not. 

The initial chapters of this report provide an orientation of ophthalmics dealmaking and business activities. Chapter 1 provides an introduction to the report. 

Chapter 2 provides an overview of the trends in ophthalmics dealmaking since 2009covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development. 

Chapter 3 provides a review of the leading ophthalmics deals since 2009. Deals are listed by headline value, signed by bigpharma and bigbiotech, most active bigpharma/bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. 

Chapters 4 and 5 provide a comprehensive listing of the top 50 bigpharma and bigbiotech companies with a brief summary followed by a comprehensive listing of opthalmics deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 

Chapter 6 provides comprehensive access to all opthalmics deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand. 

Chapter 7 provides a comprehensive directory of all opthalmics partnering deals by specific therapeutic target announced since 2009. The chapter is organized by specific opthalmics therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 

In addition, a comprehensive appendix is provided with each report of all opthalmics partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 

The report also includes numerous tables and figures that illustrate the trends and activities in ophthalmics partnering and dealmaking since 2009. 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of ophthalmics technologies and products. 

Executive Summary 

Chapter 1 – Introduction 

Chapter 2 – Trends in ophthalmics dealmaking 

2.1. Introduction            

2.2. Ophthalmics partnering over the years          

2.3. Bigpharma opthhalmics dealmaking activity  

2.4. Ophthalmics partnering by deal type 

2.5. Ophthalmics partnering by industry sector    

2.6. Ophthalmics partnering by stage of development      

2.7. Ophthalmics partnering by technology type 

2.9. Ophthalmics partnering by therapeutic indication       

2.10. Average deal terms for ophthalmology       

2.10.1 Ophthalmics headline values         

2.10.2 Ophthalmics upfront payments      

2.10.3 Ophthalmics milestone payments  

2.10.4 Ophthalmics royalty rates 

Chapter 3 – Leading ophthalmics deals 

3.1. Introduction            

3.2. Top ophthalmics deals by value        

Chapter 4 – Bigpharma opthalmics deals 

4.1. Introduction            

4.2. How to use bigpharma partnering deals       

4.3. Bigpharma ophthalmics partnering company profiles 

Allergan            

AstraZeneca     

Bayer   

Biogen Idec      

Boehringer Ingelheim    

Dainippon Sumitomo     

Eli Lilly 

Gilead Sciences            

GlaxoSmithKline           

Johnson & Johnson       

Merck & Co      

Novartis           

Otsuka 

Pfizer   

Roche  

Sanofi   

Servier 

Takeda 

Teva    

Valeant 

Chapter 5 – Ophthalmics partnering contracts directory          

5.1. Introduction            

5.2. Company A-Z         

5.3. By deal type           

Asset purchase 

Assignment      

Bigpharma outlicensing 

Co-development            

Collaborative R&D        

Co-market        

Contract service           

Co-promotion    

Development    

Distribution       

Equity purchase            

Grant    

Joint venture     

Licensing          

Litigation          

Manufacturing   

Marketing         

Option  

Promotion         

Research          

Settlement        

Sub-license      

Supply 

Termination      

Warranty          

5.4. By stage of development    

Discovery         

Marketed          

Formulation      

Phase I 

Phase II            

Phase III           

Preclinical        

Regulatory        

5.5. By technology type 

Analysis           

Assays 

Biological compounds   

Cell culture       

Cell therapy      

Clinical testing  

Devices            

Diagnostics      

Discovery tools 

Drug delivery    

Enabling technology      

Equipment        

Facilities           

Gene therapy    

Genomics         

Implant 

Industrial chemicals      

In vitro models  

Oligonucleotide 

Orphan drug     

Peptides           

Processes        

Proteomics       

Radio/Chemo-therapy   

Recombinant DNA        

Research services        

Research supplies        

RNA therapeutics          

Screening         

Small molecules           

Stem cells        

Toxicity            

Chapter 6 – Opthalmics dealmaking by therapeutic target     

6.1. Introduction            

6.2. Deals by therapeutic target 

Ophthalmics 

Age-related macular degeneration 

Blindness 

Cataracts 

Conjunctivitis 

Diabetes macular edema 

Dry eye 

Glaucoma 

Ocular hypertension 

Retinal detachment 

Retinopathy 

Uveitis 

Appendices     

Appendix 1 – Directory of ophthalmics deals by company A-Z 2009-2014 

Appendix 2 – Directory of ophthalmics deals by deal type 2009-2014   

Appendix 3 – Directory of ophthalmics deals by stage of development 2009-2014 

Appendix 4 – Directory of ophthalmics deals by technology type 2009-2014          

Appendix 5 – Partnering resource center           

  

Online partnering          

Partnering events         

Further reading on dealmaking  

Deal type definitions      

About Wildwood Ventures          

Current Partnering        

Current Agreements      

Current Reports            

Recent titles from CurrentPartnering      

Order Form – Reports   

 

Table of figures 

Figure 1: Ophthalmics partnering since 2009       

Figure 2: Bigpharma – top 50 – Ophthalmics deals since 2009 

Figure 3: Bigpharma ophthalmics deal frequency – since 2009 

Figure 4: Ophthalmics partnering by deal type since 2009 

Figure 5: Ophthalmics partnering by industry sector since 2009   

Figure 6: Ophthalmics partnering by stage of development since 2009     

Figure 7: Ophthalmics partnering by technology type since 2009  

Figure 8: Ophthalmics partnering by opthalmology target since 2009        

Figure 9: Ophthalmics deals with a headline value           

Figure 10: Ophthalmics deal headline value distribution, US$million – discovery stage      

Figure 11: Ophthalmics deal headline value distribution, US$million – preclinical stage     

Figure 12: Ophthalmics deal headline value distribution, US$million – phase I stage          

Figure 13: Ophthalmics deal headline value distribution, US$million – phase II stage         

Figure 14: Ophthalmics deal headline value distribution, US$million – phase III stage        

Figure 15: Ophthalmics deal headline value distribution, US$million – regulatory stage     

Figure 16: Ophthalmics deal headline value distribution, US$million – marketed stage       

Figure 17: Summary median headline value by stage of development, 2007-2012            

Figure 18 Ophthalmics deals with upfront payment values            

Figure 19: Ophthalmics deal upfront payment distribution, US$million – discovery stage   

Figure 20: Ophthalmics deal upfront payment distribution, US$million – preclinical stage   

Figure 21: Ophthalmics deal upfront payment distribution, US$million – phase I stage       

Figure 22: Ophthalmics deal upfront payment distribution, US$million – phase II stage      

Figure 23: Ophthalmics deal upfront payment distribution, US$million – phase III stage     

Figure 24: Ophthalmics deal upfront payment distribution, US$million – regulatory stage   

Figure 25: Ophthalmics deal upfront payment distribution, US$million – marketed stage    

Figure 26: Summary median upfront payments by stage of development, 2007-2012       

Figure 27: Ophthalmics deals with milestone payments    

Figure 28: Ophthalmics deal milestone distribution, US$million – discovery stage 

Figure 29: Ophthalmics deal milestone distribution, US$million – preclinical stage 

Figure 30: Ophthalmics deal milestone distribution, US$million – phase I stage     

Figure 31: Ophthalmics deal milestone distribution, US$million – phase II stage    

Figure 32: Ophthalmics deal milestone distribution, US$million – phase III stage   

Figure 33: Ophthalmics deal milestone distribution, US$million – regulatory stage 

Figure 34: Ophthalmics deal milestone distribution, US$million – marketed stage  

Figure 35: Ophthalmics deals with royalty rates, %          

Figure 36: Ophthalmics deal royalty rate distribution, US$million – discovery stage          

Figure 37: Ophthalmics deal royalty rate distribution, US$million – preclinical stage          

Figure 38: Ophthalmics deal royalty rate distribution, US$million – phase I stage  

Figure 39: Ophthalmics deal royalty rate distribution, US$million – phase II stage 

Figure 40: Ophthalmics deal royalty rate distribution, US$million – phase III stage            

Figure 41: Ophthalmics deal royalty rate distribution, US$million – regulatory stage          

Figure 42: Summary median royalty rate by stage of development, 2007-2012    

Figure 43: Top ophthalmics deals by value since 2009     

Figure 44: Recent deals (Jan 2007 to Nov 2012) - By therapy area (Opthalmics) 

Figure 45: Online partnering resources  

Figure 46: Forthcoming partnering events